Watts, J., Borthakur, G., Lin, T., Gabrail, N., Patel, K., Madanat, Y., Zeidner, J., Khaskhely, N., Bonham, L., Nelson, M., Kumer, J., Taylor, D., Taromino, C., Miller, M. W., Huebner, D., Maris, M. (2025). A dose optimization phase 1b/2 study evaluating mipletamig (formerly APVO436), a novel bispecific CD123 x CD3 ADAPTIRÒ molecule in combination therapy for the treatment of frontline acute myeloid leukemia (AML) in patients unfit for intensive chemotherapy. Blood. https://doi.org/10.1182/blood-2025-5198